FORTY FORT, PA -- Geisinger Health System has been awarded a $400,000 grant from the Robert Wood Johnson Foundation (RWJF) to support GenomeFIRST Medicine, a unique program to help patients and providers understand and use genomic information in their health care.
“As we enter the era of precision health, we will increasingly use genetic information to identify health risk and then use preventive strategies to avoid disease. This program is building the infrastructure to do that,” said Dr. Michael Murray (right), director of clinical genomics, Geisinger Genomic Medicine Institute. “At Geisinger, we strongly believe that genome sequencing will become more and more integrated into routine care, and that GenomeFIRST Medicine will drive medicine toward early diagnoses and disease prevention for many of our patients.”
The GenomeFIRST Medicine program takes a comprehensive approach to care that includes genomic screening, interpretation and managing results — essentially changing health care by expanding providers’ ability to care for their patients before a problem arises. With support from the Robert Wood Johnson Foundation, Geisinger will pilot a scalable model for integrating genomic results into the everyday care of 300 Geisinger patients. The project will focus on the three most common genetic conditions in Geisinger’s GenomeFIRST program: Hereditary Breast and Ovarian Cancer Syndrome (HBOC), Lynch Syndrome, and Familial Hypercholesterolemia.
“We are anticipating a future where genomic information is a routine part of care, much like temperature and blood pressure measurements are today,” said Paul Tarini, senior program officer at the Robert Wood Johnson Foundation. “But genomic information is often about potentials and risks and the data can have implications for other members of your family. What we don’t understand is how to integrate that data directly into the processes of care. The Geisinger project is testing an approach to help people and providers manage this information and is a critical step toward a Culture of Health,” he said.
Geisinger opened the Precision Health Center in Forty Fort in 2015. The 14,000-square-foot, $562,000 facility houses highly specialized teams from Geisinger's Clinical Genomics and Autism & Developmental Medicine Institute (ADMI), and serves as the primary location for Geisinger Research in Northeastern Pennsylvania.
One of the nation’s most innovative health services organizations, Geisinger serves more than 1.5 million patients in Pennsylvania and New Jersey. The system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. Geisinger is known for its focus on caring and innovative programs including the ProvenCare® best-practice approach to maximize quality, safety and value; ProvenHealth Navigator® advanced medical home; Springboard Health® population health program to improve the health of an entire community; ProvenExperience™ to provide refunds to patients unhappy with their care experience; and Geisinger’s MyCode® Community Health Initiative, the largest healthcare system-based precision health project in the world. With more than 215,000 volunteer participants enrolled, MyCode is conducting extensive research and returning medically actionable results to participants. A physician-led organization, with approximately 32,000 employees and more than 1,800 employed physicians, Geisinger leverages an estimated $12.7 billion positive annual impact on the Pennsylvania and New Jersey economies. Repeatedly recognized nationally for integration, quality and service, Geisinger has a long-standing commitment to patient care, medical education, research and community service. For more information, visit www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.